Introduction
cancer
CANCER, CERVICAL CARCINOMA
Cervical carcinomas are the second leading cause of mortality by cancer in women aged 20 to 39 years, worldwideThe introduction of T cell-targeted immunomodulators blocking the immune checkpoints (ICI) CTLA-4, PD-1, or PD-L1, which aim to harness the host immunity to fight cancer, emerged as a promising strategy in the management of several solid tumorsIn the early setting, the CALLA randomized phase-III trial (NCT03830866)